Inovio Pharmaceuticals, Inc. (INO)

Market Cap	78.48M
Revenue (ttm)	283,099
Net Income (ttm)	-96.48M
Shares Out	36.67M
EPS (ttm)	-3.11
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,923,265
Open	2.020
Previous Close	2.040
Day's Range	1.980 - 2.250
52-Week Range	1.420 - 12.330
Beta	1.31
Analysts	Buy
Price Target	9.75 (+355.61%)
Earnings Date	Aug 7, 2025

About INO

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervi...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 12, 1998
• Employees: 134
• Stock Exchange: NASDAQ
• Ticker Symbol: INO
• Website: https://www.inovio.com

Financial Performance

In 2024, Inovio Pharmaceuticals's revenue was $217,756, a decrease of -73.83% compared to the previous year's $832,010. Losses were -$107.25 million, -20.62% less than in 2023.

Analyst Summary

According to 4 analysts, the average rating for INO stock is "Buy." The 12-month stock price target is $9.75, which is an increase of 355.61% from the latest price.

Price Target

$9.75

(355.61% upside)

Analyst Consensus: Buy